Hansoh Pharmaceutical (03692): Class 1 New Drug HS-20136-2 Injection Receives Two IND Approvals from NMPA for Type 2 Diabetes and Weight Management

Zhitong Finance APP News: Hansoh Pharma (03692) announced that the Group’s independently developed Class 1 new drug, HS-20136-2 injection, has received two Drug Clinical Trial Approval Notices from the National Medical Products Administration (NMPA) of China, for conducting clinical trials for “type 2 diabetes” and “weight management,” respectively.